Login / Signup

An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission.

Luca BiavatiCarol Ann HuffAnna FergusonAmy SidorskiM Amanda StevensLakshmi RudrarajuCristina ZucchinettiSyed Abbas AliPhilip ImusChristian B GockeRachel M GittelmanSarah A JohnsonCatherine SandersMarissa VignaliAnita GandhiXiaobu YeKimberly A NoonanIvan Borrello
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
MM-GVAX, along with lenalidomide, effectively primed durable immunity and resulted in long-term disease control, as suggested by the reappearance of a detectable, fluctuating M-spike without meeting the criteria for clinical relapse. For patients in a nCR, MM-GVAX administration was safe and resulted in prolonged clinical responses.
Keyphrases
  • newly diagnosed
  • multiple myeloma
  • end stage renal disease
  • ejection fraction
  • stem cell transplantation
  • prognostic factors
  • rheumatoid arthritis
  • high dose